Concepedia

H. S. Hochster

HS

Statistics

Publications

13

Citations

652

H-Index

13

Active since

1989

Affiliations

New York University(Current)

Columbia University Irving Medical Center

University of Maryland, Baltimore

BC Cancer Agency

Sarah Cannon

H. S. Hochster is an author at New York University specializing in oncology, medicine, and chemotherapy.

Publications per year

1989–2016

13

Publications

13

Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study

H. S. Hochster, Lowell L. Hart, Ramesh K. Ramanathan et al. · Journal of Clinical Oncology · 2006 · 137 citations

, , +14

Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial

Axel Grothey, Lowell L. Hart, K. M. Rowland et al. · Journal of Clinical Oncology · 2008 · 113 citations

, , +17

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

Carolyn Wasserheit, Andrea Frazein, Ruth Oratz et al. · Journal of Clinical Oncology · 1996 · 87 citations

, , +15

Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)

H. S. Hochster, Edie Weller, Thomas M. Ryan et al. · Journal of Clinical Oncology · 2004 · 74 citations

, , +13

Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

H. S. Hochster, Lauri Welles, L. Hart et al. · Journal of Clinical Oncology · 2005 · 58 citations

, , +12

1–5 of 13